New arthritis drug candidate enters early human safety testing

NCT ID NCT06628206

Recruiting now Symptom relief Sponsor: LAPIX Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests an experimental drug called LPX-TI641 in 48 adults with rheumatoid arthritis or psoriatic arthritis. Participants take the drug or a placebo daily for 28 days. The main goal is to check if the drug is safe and tolerable, and how it moves through the body. This is a Phase 1 trial, so it focuses on safety, not yet on how well it treats the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSORIATIC ARTHRITIS (PSA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriatic arthritis rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PSORIATIC ARTHRITIS (PSA) RHEUMATOID ARTHRITIS (RA)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Triumpharma Clinical Research Unit at AlEssra Hospital
RECRUITING

Amman, ST B204, Jordan

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.